What happened
- Erasca, a San Diego drugmaker, reported early results for ERAS‑0015, a once-daily pill aimed at mutant RAS, the driver found in about 95% of pancreatic cancers.
- As reported by CTV News: tumours shrank substantially in 44% of 25 people with advanced pancreatic cancer on a 32 mg daily dose, and in 3 of 5 people with lung cancer who had already had immunotherapy and chemotherapy.
- Erasca says late-stage trials of ERAS‑0015 and a second drug, ERAS‑4001, start in 2027. Princess Margaret Cancer Centre in Toronto is expected to be a site.
What we don't know yet
- These are company-reported numbers from a phase 1 trial. They have not been peer reviewed.
- Tumour shrinkage is not the same as living longer. There is no control group yet.
- Erasca's April 2026 update reported one death from treatment-related lung inflammation (pneumonitis), per a summary of the company's call.
Primary sources
- ClinicalTrials.gov record NCT06983743 (phase 1, recruiting)Trial registry
- CTV News, 22 Nov 2026News report
- MarketBeat summary of Erasca's April 2026 data callNews report
Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.